Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== Reactivity == As a simple, abundant and bifunctional compound, pyruvic acid has been shown to participate in many reactions. Pyruvate reacts with amino acids to give alanine by the process called transamination:
The lack of a separate chromosome 17 probe on the same section is an issue with regards to acceptance of CISH. As of June 2011 Roche has obtained FDA approval for the INFORM HER2 Dual ISH DNA Probe cocktail developed by Ventana Medical Systems. The DDISH (Dual-chromagen/Dual-hapten In-situ hybridization) cocktail uses both HER2 and Chromosome 17 hybridization probes for chromagenic visualization on the same tissue section. The detection can be achieved by using a combination of ultraView SISH(silver in-situ hybridization) and ultraView Red ISH for deposition of distinct chromgenic precipitates at the site of DNP or DIG labeled probes.
Herein, the electron donor NADPH is used as the reducing agent, ultimately converting the β-keto group of β-ketoacyl-ACP into the β-hydroxyl group of β-hydroxyacyl-ACP. The fifth step of fatty acid elongation is the dehydration of β-hydroxyacyl-ACP to enoyl-ACP, in a reaction catalyzed by 3-hydroxyacyl-ACP dehydratase. 3-hydroxyacyl-ACP dehydratase removes one molecule of H2O to form a double bond between the C2–C3 carbons of β-hydroxyacyl-ACP, thereby saturating the chain and producing enoyl-ACP. The sixth step of fatty acid elongation is the reduction of enoyl-ACP to butyryl-ACP, in a reaction catalyzed by enoyl-ACP reductase. Herein, enoyl-ACP reductase reduces the C2–C3 double bond of enoyl-ACP into a saturated acyl-ACP using one molecule NADPH as the electron donor. The production of butyryl-ACP thus marks the completion of the first cycle of fatty acid elongation, and the reaction sequence thereafter repeats again (condensation → reduction → dehydration → reduction). At the beginning of the second cycle, butyryl-ACP condenses with a molecule of malonyl-ACP, forming the six-carbon β-ketoacyl-ACP molecule and one molecule of CO2. The next three reactions within the second cycle (reduction → dehydration → reduction) convert the six-carbon β-ketoacyl-ACP into a six-carbon ACP molecule, which thus marks the completion of the second cycle of fatty acid elongation, and a third cycle can thereafter begin. These elongation cycles continue (x7) until a (16C) acyl-ACP molecule is formed.
Sources: en.wikipedia.org
=== 2000-present === In 2000, the company opened a central laboratory in Singapore, building on clinical-development services formed in Singapore in 1996. In 2013, it expanded the capacity of the laboratory by 50%. In March 2001, the company sold Covance Pharmaceutical Packaging Services to Fisher Scientific for $137.5 million. In August 2005, it acquired GFI Clinical Services, an 80-bed clinical pharmacology business, from West Pharmaceutical Services for $5.7 million. In April 2006, the company acquired eight early phase clinical pharmacology sites from Radiant Research for $65 million. In June 2006, it acquired Signet Laboratories, a provider of monoclonal antibodies used in the research of cancer, infectious disease, and neurodegenerative disease, for $8.95 million. In 2007, the company opened a laboratory in Shanghai, China. In 2019, it opened a research and development center in Shanghai. In August 2008, the company acquired a campus in Greenfield, Indiana from Eli Lilly and Company and executed a 10-year service drug development service agreement with Lilly. In December 2008, the company acquired a minority equity stake in Caprion Proteomics, a provider of proteomics-based services to the pharmaceutical industry. The company was acquired by Chicago Growth Partners in July 2012. In 2009, the company acquired the Gene Expression Laboratory from Merck & Co. and entered into a five-year, $145 million contract to provide Merck with genomic analysis services.
In Portugal, public prosecution is conducted by the Public Prosecution Service which is headed by the prosecutor general. The main police organisations of Portugal are the Guarda Nacional Republicana (National Republican Guard), the Polícia de Segurança Pública (Public Security Police), a civilian police force that works in urban areas; and the Polícia Judiciária (Judiciary Police), a senior criminal police body, under the authority of the Minister of Justice and endowed with administrative autonomy. Portugal has 49 correctional facilities run by the Directorate-General for Reintegration and Prison Services (DGRSP). The facilities are classified by security level, and by degree of management complexity, and often house inmates with different legal statuses, risk levels, and criminal trajectories within the same facilities. Despite following a reintegration-oriented penal model, Portugal retains high prison occupancy and an average sentence length of 31.3 months and one of the world's highest prison suicide rates representing around 30% of the 60 to 70 deaths occurring annually.
11 May – The Independent Press Standards Organisation rejects a complaint by former MP Scott Benton that an article published by The Times in April 2023 was in breach of IPSO's editors code. 12 May – Foreign Secretary David Cameron tells the BBC's Sunday with Laura Kuenssberg that a ban on the sale of UK weapons to Israel would only strengthen Hamas. Former Chancellor Nadhim Zahawi tells BBC News he has paid nearly £5m to authorities to settle his tax affairs. 13 May – The House of Commons approves plans to exclude MPs from the parliamentary estate if they have been arrested on suspicion of a serious offence. Health secretary Victoria Atkins says that more maternity care scandals are likely following a birth trauma report on maternity care services. Labour MP Rosie Duffield calls for the party to suspend Natalie Elphicke while investigating lobbying allegations. Labour MP Chris Bryant reveals he has skin cancer. A judge at the Northern Ireland High Court rules that the UK government's Illegal Migration Act should not apply in Northern Ireland because of human rights laws and the Windsor Framework. The UK government scraps a planned amendment to the Criminal Justice Bill that would give police the power to move homeless people on because of "smells" following opposition from Conservative MPs. 14 May – MSPs unanimously approve the Housing Cladding Remediation Bill with 116 votes in favour of the legislation that seeks to address problems with cladding on buildings and avoid a similar incident to the Grenfell Tower fire in Scotland.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.